ABL Diagnostics lands global tenders as distribution expands

By AI, Created 7:46 AM UTC, May 27, 2026, /AGP/ – ABL Diagnostics said it won multiple public tenders and commercial contracts across Europe, Asia, Africa and North America in the first half of 2026, adding to its global push in sequencing-based HIV and hepatitis diagnostics. The deals and broader distributor network could deepen recurring revenue as hospitals and reference labs move toward validated molecular testing platforms.

Why it matters: - ABL Diagnostics is broadening its international footprint in molecular diagnostics at a time when sequencing-based testing is gaining adoption in infectious disease labs. - The new contracts add to recurring business tied to HIV and hepatitis workflows, which supports the company’s long-term growth strategy. - The company’s platform-agnostic model may help labs adopt its tools without buying new sequencing hardware.

What happened: - ABL Diagnostics announced a series of commercial wins secured in the first half of 2026. - The company and its local distribution partners won multiple public tenders and corporate contracts across Europe, Asia, Africa and North America. - The agreements span France, the United States, Spain, Finland, Greece, Türkiye, Moldova, India and Botswana. - The contracts mainly support sequencing-based workflows for HIV and hepatitis management.

The details: - The tender scope includes targeted assays for HIV genotyping and hepatitis virus characterization, including HBV, HCV and HDV. - The agreements also cover end-to-end workflows used in public hospital laboratories, national reference centers and private laboratory networks. - Financial terms were not disclosed because of local public procurement restrictions. - ABL Diagnostics said the contracts create a strong recurring business base over the coming years. - The company’s bioinformatics and assay solutions are designed to work with existing third-party infrastructure. - The software ecosystem supports data from Illumina, MGI, Oxford Nanopore Technologies and Thermo Fisher Scientific Sanger systems. - The DeepChek technology can be implemented without capital spending on new hardware, according to the company. - ABL Diagnostics markets PCR detection under UltraGene and DNA sequencing genotyping under DeepChek®. - The company also sells HIV drug-resistance testing, including a whole-genome kit, as well as advanced detection solutions for SARS-CoV-2, tuberculosis, hepatitis B and C. - The portfolio includes microbiome and taxonomy analyses based on 16s/18s RNA and molecular assays for other viral and bacterial targets. - Integrated products include real-time syndromic PCR tests, Nadis® patient medical record software used in more than 200 hospitals in France for HIV and hepatitis management, and MediaChek® clinical sample collection kits. - ABL Diagnostics has also been marketing products and services from sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement. - The company is headquartered in Woippy, France, and is listed on compartment B of Euronext Paris under ABLD and ISIN FR001400AHX6.

Between the lines: - The announcement points to a market shift away from in-house laboratory-developed tests and toward standardized, clinically validated IVD solutions, especially in Europe. - ABL Diagnostics is positioning itself to benefit from demand linked to antimicrobial resistance monitoring, epidemiological tracking and broader public health surveillance. - The company’s distributor network across all continents suggests a commercial model built for scale rather than a single-market launch. - The cited market forecasts underscore why sequencing and molecular infectious disease testing remain attractive categories for diagnostics investors and buyers.

What’s next: - ABL Diagnostics expects the new contracts to contribute to recurring revenue in the coming years. - The company is likely to keep expanding tender activity and distributor coverage as laboratories adopt more sequencing-based infectious disease testing. - Management expects the regulatory shift toward validated commercial IVDs to widen the addressable market for its assays and decision-support tools. - Grand View Research estimates the global infectious disease sequencing market was about $1.9 billion in 2023 and could grow at a 24.6% CAGR through 2030. - MarketsandMarkets estimates the molecular infectious disease testing market could rise from $11.3 billion in 2026 to more than $19 billion by 2031.